Replies to post #88560 on Anavex Life Sciences Corp (AVXL)

[bas2020]

Interesting scenario, but don't you think we'll have Alz P3 underway well before 2-73 is approved for Rett's? Early results of Alz P3 should show consistent efficacy with, both, previous Alz P2a results and Rett's P2.

Question remains: who is the partner that manufactures, markets and distributes the drug for Rett's?

[Millstone]

If A2-73 continues to demonstrate both the amelioration of symptoms in some Alzheimer's patients and the reversal of the disease in others, I am very confident that this scenario will happen. We need 1) success in the Rett Syndrome trial and 2) FDA approval of A2-73 for Rett.

If the above occurs, insurance companies will LOVE Anavex, and doctors will come to love Anavex as well.

Of course patients and their families will be overjoyed, and Anavex will love them back. A win-win-win.

[HANUMAN]

I wouldn't be so confident that insurance companies will do the logical thing (covering an off-label use of a new drug), when it is obvious that in the long run it will save them money. I know of several new(at the time) drugs used by orthopedists that were both superior and cheaper than the old "gold standard" drugs, yet we had to jump through tedious hoops to get them authorized, or flat out didn't even try. They know that throwing up needless roadblocks will cause the applicant to not even try, not to mention the time the physician or staff have to put in for free. BTW, did you get the PM I sent last Friday?